Natco Pharma Limited (NATCOPHARM)
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation - Q1FY27
- Total Revenue 7.94bn INR; EBITDA 2.46bn INR; EBITDA margin 30.9% (Q4FY26: 25.1%); PAT 2.07bn INR; PAT margin 26%
- International formulations revenue 4.77bn INR; Domestic formulations 1.36bn INR
- Profit share from associate Adcock Ingram Holdings 843mn INR
- Received final approval for Eribulin Mesylate Injection from US FDA
- Ongoing clinical trials and investments in NCE, cell & gene therapy with FDA approvals for xenotransplantation studies
- Earnings call scheduled on 14-Aug-2026 at 17:30 IST
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 NATCOPHARM — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add NATCOPHARM to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Natco Pharma Limited
Important.
The summary above is generated automatically from Natco Pharma Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.